This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Reflections on Reperfusion
* Evolution of Timing of Pharmacologic Reperfusion
* Primary PCI: The Need for Excellence
* PPCI in STEMI: Time & Risk
* Clinical Outcomes
* PPCI vs Fibrinolysis for STEMI
* Primary 30-day Endpoint DANAMI-2
* DANAMI-2: Reflections on NEJM Publication
* DANAMI-2: 3-yr Mortality & Risk A New Perspective
* Survival Advantage: PPCI vs Lytics
The moderator, Kristin Newby, MD, has indicated that she receives research/grant support
from Bristol-Myers Squibb, Sanofi, Millennium Pharmaceuticals, Inc., Schering-Plough
Research Institute, Novartis and Roche Diagnostics Corporation. Dr. Newby is also a member
of an advisory board for Eli Lilly and a consultant for Proctor and Gamble; she has spoken
at scientific symposia for Aventis, Bristol-Myers Squibb, Sanofi and Millennium
Pharmaceuticals, Inc.
The guest faculty, Paul W. Armstrong, MD, has indicated that he receives research/grant
support from Boehringer-Ingelheim, Hoffman-LaRoche and sanofi-aventis. He also serves as a
consultant for sanofi-aventis and Hoffman-LaRoche.
|
|